Cellebrite DI (NASDAQ:CLBT) Posts Earnings Results, Beats Expectations By $0.06 EPS

Cellebrite DI (NASDAQ:CLBT) issued its earnings results on Thursday. The company reported $0.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.05 by $0.06, FiscalAI reports. The firm had revenue of $131.14 million for the quarter, compared to analysts’ expectations of $131.87 million. Cellebrite DI had a net margin of 14.48% and a return on equity of 18.38%.

Here are the key takeaways from Cellebrite DI’s conference call:

• Q2 ARR and revenue fell short of expectations, with ARR rising 21% to $508 million but missing the low end of guidance. Several large government transactions slipped because of new procurement, foreign-entity permitting, and cloud/AI approval requirements.
• Cellebrite reduced its full-year 2026 outlook to $550 million–$560 million of ARR and $555 million–$561 million of revenue, citing slower Inseyets pricing and expansion, elongated deal cycles, and greater caution around large transactions.
• The company raised its full-year adjusted EBITDA outlook to $153 million–$159 million, or a 28% margin, while maintaining confidence in improving free cash flow as headcount remains essentially flat and FX headwinds eventually ease.
• New products are gaining traction: growth products contributed 25% of the sequential ARR increase, Genesis generated about $400,000 of ARR shortly after its launch, and Guardian secured a first major FedRAMP deal with a seven-figure initial order.
• Shiv Ramji became CEO effective immediately in an accelerated succession from Tom Hogan, reflecting the board’s preference for a product-centric leader focused on cloud-native platforms and AI; Cellebrite said the transition has the support of the management team.

Cellebrite DI Stock Performance

Shares of NASDAQ CLBT traded up $0.34 during midday trading on Friday, hitting $11.14. 7,835,542 shares of the company’s stock traded hands, compared to its average volume of 2,139,398. The stock has a market capitalization of $2.78 billion, a price-to-earnings ratio of 39.79, a price-to-earnings-growth ratio of 1.89 and a beta of 1.18. The firm has a fifty day moving average of $14.52 and a 200 day moving average of $14.05. Cellebrite DI has a 1 year low of $9.58 and a 1 year high of $19.98.

Insider Activity

In other Cellebrite DI news, CEO Thomas E. Hogan sold 139,713 shares of the stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $15.39, for a total value of $2,150,183.07. Following the completion of the sale, the chief executive officer owned 790,548 shares in the company, valued at approximately $12,166,533.72. This represents a 15.02% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO David Barter sold 41,734 shares of the company’s stock in a transaction that occurred on Wednesday, July 8th. The stock was sold at an average price of $16.38, for a total value of $683,602.92. Following the completion of the transaction, the chief financial officer owned 334,219 shares of the company’s stock, valued at $5,474,507.22. The trade was a 11.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 297,934 shares of company stock valued at $4,631,972 in the last ninety days. Corporate insiders own 5.70% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Towarzystwo Funduszy Inwestycyjnych PZU SA lifted its holdings in Cellebrite DI by 81.0% during the 4th quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 1,900 shares of the company’s stock valued at $34,000 after buying an additional 850 shares in the last quarter. Advisory Services Network LLC bought a new position in Cellebrite DI in the 3rd quarter worth about $40,000. Vestcor Inc bought a new position in Cellebrite DI in the 3rd quarter worth about $70,000. Pacer Advisors Inc. increased its position in shares of Cellebrite DI by 45.1% during the fourth quarter. Pacer Advisors Inc. now owns 3,981 shares of the company’s stock worth $72,000 after acquiring an additional 1,238 shares during the period. Finally, Barclays PLC raised its stake in shares of Cellebrite DI by 131.5% during the fourth quarter. Barclays PLC now owns 6,305 shares of the company’s stock valued at $114,000 after acquiring an additional 3,582 shares in the last quarter. Institutional investors own 45.88% of the company’s stock.

Cellebrite DI News Roundup

Here are the key news stories impacting Cellebrite DI this week:

• Positive Sentiment: Analysts continue to see upside despite reducing their estimates. JPMorgan lowered its price target from $20 to $16 while retaining an Overweight rating; D.A. Davidson cut its target from $22 to $15 but maintained Buy; and Needham reduced its target from $15 to $12.50 while also keeping a Buy rating. The revised targets remain above the recent trading level. Analyst price-target updates
• Positive Sentiment: Second-quarter adjusted EPS of $0.11 exceeded the commonly cited analyst estimate of $0.05, and subscription revenue continued to grow. Management also raised its adjusted EBITDA target, providing some support for profitability. Cellebrite earnings release
• Positive Sentiment: Unusually heavy call-option activity, with nearly 20,000 contracts traded versus average volume of about 586, suggests some traders are positioning for a rebound. This is a speculative signal rather than a change in fundamentals.
• Neutral Sentiment: Cellebrite completed a planned CEO succession, appointing Shiven Ramji to replace Thomas E. Hogan. The transition could lead to a strategic reset, but it also adds uncertainty as investors reassess the company’s growth plans. CEO succession announcement
• Negative Sentiment: The primary catalyst for the decline was weaker forward guidance. Third-quarter revenue is forecast at $145 million-$148 million, below the $150.3 million consensus, while full-year revenue guidance of $555 million-$561 million trails the $568.1 million estimate. Cellebrite also reduced its 2026 annual recurring revenue outlook, signaling slower growth.
• Negative Sentiment: Revenue of $131.14 million slightly missed expectations of $131.87 million, and ARR reportedly fell short of prior guidance. The revenue and recurring-revenue misses outweighed the quarterly EPS beat. Cellebrite Q2 earnings analysis
• Negative Sentiment: Multiple law firms announced investigations into potential securities-law violations and whether previous projections and disclosures were accurate. These are allegations, not findings, but they increase legal and reputational risk. Cellebrite investigation notice
• Negative Sentiment: Outgoing CEO Thomas Hogan sold 139,713 shares worth approximately $2.15 million, reducing his holdings by about 15%. While the sale may reflect the leadership transition or personal financial planning, its timing weighs on investor sentiment. SEC insider trading filing

Wall Street Analysts Forecast Growth

Several research analysts have commented on CLBT shares. JPMorgan Chase & Co. decreased their price objective on shares of Cellebrite DI from $20.00 to $16.00 and set an “overweight” rating for the company in a report on Friday. Needham & Company LLC cut their target price on shares of Cellebrite DI from $15.00 to $12.50 and set a “buy” rating on the stock in a research note on Friday. Weiss Ratings upgraded shares of Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, May 18th. Lake Street Capital decreased their price target on shares of Cellebrite DI from $21.00 to $15.00 and set a “buy” rating for the company in a research note on Friday. Finally, DA Davidson cut their price objective on Cellebrite DI from $22.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday. Five investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, Cellebrite DI presently has a consensus rating of “Moderate Buy” and an average price target of $16.70.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.